Johnson & Johnson Q1 2026 Earnings Recap

JNJ Q1 2026 April 14, 2026

Get alerts when JNJ reports next quarter

Johnson & Johnson delivered a robust Q1 2026 with 6.4% operational sales growth, driven by strong performances across its innovative pharma and MedTech segments, and raised full-year guidance toward $100 billion revenue.

Earnings Per Share Beat

$2.70 vs $2.68 est.

+0.7% surprise

Revenue Beat

24062000000 vs 23614670000 est.

+1.9% surprise

Market Reaction

1-Day +0.9%

5-Day -1.59%

30-Day -5.61%

See JNJ alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q1 revenue grew 6.4% annually, with Innovative Medicine up 7.4% and MedTech up 4.6%, reflecting broad-based momentum.
Oncology led with 18% growth in DARZALEX and FDA approvals for TECVAYLI and CARVYKTI, expanding pipeline impact.
Immunology sales surged 64%, driven by TREMFYA, and FDA approval of ICOTYDE positions the company for significant market share in immunology.
MedTech’s cardiovascular segment showed strength in ablation and circulatory recovery, with innovative platforms like VARIPULSE and OMNYPULSE gaining traction.
The company remains on track for $100 billion in 2026 revenue, with confidence in sustained double-digit growth through 2027.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit JNJ on AllInvestView.

Previous Q3 2025